L-type calcium channel antagonists are uncommon causes of myoclonus, and the underlying mechanism remains unclear. Here, we report a case of parkinsonian syndrome with deterioration of preexisting myoclonus after nifedipine use. A 96-year-old woman was administered a single dose of sustained-release nifedipine for chest pain. One hour later, the patient developed shock-like jerky movements in the trunk and upper and lower limbs. Neurological examination revealed myoclonus, intention tremor in both hands, facial hypomimia, stooped posture, short stride length, absent arm swing during walking, and muscle rigidity in the neck, left arm, and both legs. Brain magnetic resonance imaging showed no causative lesions, suggesting a nifedipine-induced movement disorder. Myoclonic movements almost completely resolved within 24 h. Despite no further administration of nifedipine, a neurological examination one week later revealed parkinsonism with mild myoclonus and intention tremor. It appeared that preexisting myoclonus and intention tremor transiently worsened with nifedipine use. The patient was diagnosed with parkinsonian syndrome with deterioration of myoclonus due to nifedipine administration. This case suggests that the corticostriatal pathways may have already been impaired and were further affected by nifedipine. Nifedipine-induced alterations in dopaminergic and serotonergic systems may have contributed to the deterioration of myoclonus and intention tremor. When patients present with myoclonus after taking an L-type calcium channel antagonist, underlying neurological disorders should be carefully investigated.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732187 | PMC |
http://dx.doi.org/10.1016/j.ensci.2024.100545 | DOI Listing |
eNeurologicalSci
March 2025
Department of Neurology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.
L-type calcium channel antagonists are uncommon causes of myoclonus, and the underlying mechanism remains unclear. Here, we report a case of parkinsonian syndrome with deterioration of preexisting myoclonus after nifedipine use. A 96-year-old woman was administered a single dose of sustained-release nifedipine for chest pain.
View Article and Find Full Text PDFJ Epilepsy Res
December 2024
Department of Neurology, Comprehensive Epilepsy Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Lance Adams syndrome (LAS) is characterized by chronic action or intention myoclonus resulting from cerebral hypoxia. Perampanel, a non-competitive antagonist of aamino-3-hydroxy-5methyl-4 isooxazoleproprionic acid glutamate receptor, has demonstrated some efficacy in myoclonic epilepsy and other types of myoclonus. We report significant benefit in a patient with LAS treated with add on perampanel and provide a review of the relevant literature.
View Article and Find Full Text PDFCerebellum
August 2024
Pediatric Clinic, Institute for Mother and Child Healthcare of Serbia, Belgrade, Serbia.
The aim of our study is to define the most frequent etiology, clinical presentation, and predictive factors of outcome in children with acute ataxia (AA) and to determine "the red flags" in the diagnostic approach to children with AA. The retrospective study included the patients with AA treated in the institute from 2015 to 2021. The inclusion criteria were children aged 1-18 years, evolution time of ataxia within 72 h, and diagnosis made by a physician.
View Article and Find Full Text PDFEpilepsy Behav Rep
October 2023
1st Department of Neurology, Institute of Psychiatry and Neurology, Sobieskiego 9 Street, 02-957 Warsaw, Poland.
Progressive myoclonic epilepsy (PME) is characterized by prominent myoclonus, generalized tonic-clonic seizures, and less often focal, tonic, or absence seizures. The KCNC1 mutation is responsible for specific clinical phenotype of PME which has been defined as myoclonic epilepsy and ataxia due to potassium channel mutation (MEAK). We present a case of a 44 years-old male patient with genetically proven MEAK who underwent subthalamic nucleus/substantia nigra (STN/SNr) deep brain stimulation (DBS) for his pharmacological-refractory myoclonus and drug-resistant epilepsy (DRE).
View Article and Find Full Text PDFGenes (Basel)
September 2023
Department of Pediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.
Biallelic variants in the Golgi SNAP receptor complex member 2 gene () have been reported in progressive myoclonus epilepsy with neurodegeneration. Typical clinical features include ataxia and areflexia during early childhood, followed by seizures, scoliosis, dysarthria, and myoclonus. Here, we report two novel patients from unrelated families with a -related disorder and novel genetic and clinical findings.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!